DownRightNowNews
Trending
OpenAI has solved the Navier-Stokes Millennium problem using $15m of AI effortExclusive – Secretary Scott Bessent: If China ‘Were to Pull Ahead of Us on AI, Nothing Else Matters’More than 600 flights in and out of U.K. cancelled due to air traffic control issueVocational education teachers threaten poll boycott over yearNo contradiction between respect to Ma Durga and our creative freedom: Theme artistsPunjab enforces ‘no work, no pay’ rule as employees extend strike till Sept 11Jaipur heritage, two roadmaps: BJP’s broad promise vs Cong’s 50Bybit Adds 24/7 FX Majors to Its Crypto Derivatives AccountOpenAI has solved the Navier-Stokes Millennium problem using $15m of AI effortExclusive – Secretary Scott Bessent: If China ‘Were to Pull Ahead of Us on AI, Nothing Else Matters’More than 600 flights in and out of U.K. cancelled due to air traffic control issueVocational education teachers threaten poll boycott over yearNo contradiction between respect to Ma Durga and our creative freedom: Theme artistsPunjab enforces ‘no work, no pay’ rule as employees extend strike till Sept 11Jaipur heritage, two roadmaps: BJP’s broad promise vs Cong’s 50Bybit Adds 24/7 FX Majors to Its Crypto Derivatives Account
Health

Postmemory: delineating the impact of trauma on the generation

·1h ago
Share:PostShare

Coined by American philosopher Marianne Hirsch, postmemory describes the relationship of the subsequent generation to the traumatic experiences of the previous generation, which they did not directly experience but ‘remember’ through stories and experiences transmitted to them

T

The Hindu

Original source

Read full story

the hindu

Check live status on DownRightNow

Check status →
WorldSportsAutomotive

Related Stories

Health7h ago

AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group

REDWOOD CITY, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- AirNexis Therapeutics, Inc. ("AirNexis"), a clinical-stage biotech company developing therapeutics for pulmonary diseases, today announced results from a Phase 2b study of AN01, a dual PDE3/4 inhibitor DPI. The study, HSK39004-T1-202, was conducted in China by AirNexis' partner Haisco Pharmaceutical Group ("Haisco"). The Phase 2b study enrolled patients with chronic obstructive pulmonary disease (COPD) receiving background therapy of single or dual bronchodilator maintenance therapy who remained symptomatic despite such treatment. Data were presented earlier today at the 2026 European Respiratory Society (ERS) Congress in Barcelona, Spain. The ePoster will be available on the conference's website. AirNexis licensed AN01 (HSK39004 in China) from Haisco, which is developing the asset for the Greater China market; AirNexis holds development rights outside China.

GGlobe Newswire
Health7h ago

Australian pollen season may be arriving early in eastern states

Australian pollen season may be arriving early in eastern states Medical Xpress Has hay fever season started early? And what’s the most common culprit? The Conversation What you need to know about seasonal illnesses this spring SBS Expat reveals health condition that's much worse in Australia: 'Every night at 4am' au.news.yahoo.com

GGoogle News

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer